Adult-onset Still’s disease biological treatment strategy may depend on the phenotypic dichotomy
François Vercruysse(Centre Hospitalier Universitaire de Bordeaux), Marie‐Elise Truchetet(Centre National de la Recherche Scientifique), François Lifermann(Centre Hospitalier de Dax –Côte d’Argent), Christophe Richez(Boston University), Thomas Barnetche(Université de Bordeaux), Estibaliz Lazaro(Centre National de la Recherche Scientifique), Thierry Schaeverbeke(Inserm), Alexandre Balageas(Centre Hospitalier De Pau), X. Delbrel(Centre Hospitalier De Pau), Émilie Shipley(Centre Hospitalier de Dax –Côte d’Argent), Bruno Fautrel
Cited by 75
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease
|New England Journal of Medicine|2018|501
Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients*
|British Journal of Dermatology|2021|414